Neurolixis Inc. has been awarded a grant by the Rett Syndrome Research Trust (RSRT) to carry out a pharmacokinetic and plasma dosing study of its clinical asset, NLX-101. The latter is being developed as a treatment for Rett syndrome, a debilitating genetic disorder. Among other symptoms, Rett syndrome is associated with serious breathing difficulties which are anticipated to be attenuated by NLX-101. The grant from RSRT will support dosing studies in preparation for proof-of-concept clinical trials.

Read the full press announcement:  pdf_symbol.

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: